Corrigendum to real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States [Urologic oncology: Seminars and original investigations 40 (2022) 195.e1−195.e11] (Urologic Oncology: Seminars and Original Investigations (2022) 40(5) (195.e1–195.e11), (S107814392100510X), (10.1016/j.urolonc.2021.11.014))

The authors regret that the legend for Figure 2 included additional words that inadvertently changed the meaning. The legend for the 3-panel figure was intended to describe the proportions of patients in each line of therapy, and in each cisplatin-eligibility group, who received less common regimens. The word “were” was erroneously added several times in the legend, and this resulted in the proportions appearing to refer to the percentage of patients in each line of therapy who were included in each group of cisplatin eligibility, instead of those who received less common therapies. Please see below for corrected version. Fig. 2. Treatment patterns across cisplatin eligibility groups including the 5 most common regimens in any subgroup. 2L = second-line; 3L = third-line, cis. = cisplatin. The 5 most common treatment regimens of each cisplatin eligibility subgroup are shown and, if applicable, the frequency of any regimens among the 5 most common of other subgroups. N = patients who received any 1L treatment (panel A), any 2L (panel B), and any 3L (panel C) therapy. Of patients who received any 1L therapy, 75 (4.3%) cisplatin-eligible, 331 (14.4%) cisplatin-ineligible, 86 (14.0%) cis.-eligible but not receiving cis., and 217 (18.4%) eligibility-unknown patients received other less common 1L regimens. Of patients who received any 2L therapy, 238 (27.7%) cisplatin-eligible, 246 (32.0%) cisplatin-ineligible, 88 (30.9%) cis.-eligible but not receiving cis., and 177 (36.4%) eligibility-unknown patients received other less common regimens. Of patients who received any 3L therapy, 137 (43.6%) cisplatin-eligible, 96 (36.8%) cisplatin-ineligible, 35 (35.4%) cis.-eligible but not receiving cis., and 73 (38.6%) eligibility-unknown patients received other less common regimens. The authors would like to apologize for any inconvenience caused.